Turnkey Plant Designed to Budg.

Plant Contracting for the Pharmaceutical Industry


Whilst turnkey plants are nothing new to the chemical industry, in the past
this model was not very common in the pharmaceutical industry. However,
increasing time and cost constraints are changing the situation. For the
construction of both biotechnological and active-ingredients plants, general
contractors are increasingly taking overall responsibility. „Design-to-budget“
is the new formula assuring worldwide customer satisfaction in the
pharmaceutical industry. Two out-standing
projects presently being executed in Europe by Lurgi Life
Science GmbH (Germany) are the multi-product plants for Boehringer
Ingelheim Pharma KG (Germany) and Rohner AG (Switzerland).

Heftausgabe: International (englisch) 2000